Two more drug giants are joining TrumpRx, and the fine print exposes just how much of America’s “drug price crisis” is really an insurance-and-list-price shell game that leaves the uninsured holding the bag.
Quick Take
- AbbVie and Genentech are set to begin offering discounted medications through the White House’s TrumpRx site, bringing the platform to 10 and 11 participating companies.
- AbbVie’s Humira is listed at $950, representing an 86% discount off a list price above $6,900 for uninsured patients.
- Genentech’s flu drug Xofluza is listed at $50, down from $168, under a deal the White House previously announced.
- The discounts are limited to uninsured Americans or people paying out of pocket, not to most insured patients who use traditional pharmacy and insurer channels.
AbbVie and Genentech expand TrumpRx’s roster and drug list
AbbVie and Genentech are expected to “officially launch” on TrumpRx as early as Monday, according to reports that describe them as the 10th and 11th companies to join the White House-backed discount site.
The platform, launched in February 2026 with roughly 40 drugs, is now described as carrying more than 61 medications as new products and manufacturers are added. Amgen is also expanding its participation with additional drugs.
CBS News Exclusive: Drug-making giants Abbvie and Genentech will start selling medications at a discount soon on TrumpRx. https://t.co/vo4KCd2bkX
— CBS News (@CBSNews) April 6, 2026
TrumpRx’s newest headline item is AbbVie’s Humira (adalimumab), widely used for conditions such as rheumatoid arthritis and Crohn’s disease.
The deal is framed around list-price relief for patients without coverage: the White House described a price of $950, an 86% discount compared with a list price above $6,900 for uninsured patients.
Genentech, a Roche subsidiary, is listing the flu treatment Xofluza for $50, down from $168.
Who qualifies: uninsured and full out-of-pocket patients only
The eligibility guardrails are the biggest practical limitation. The reporting describes TrumpRx discounts as available to uninsured patients and to people paying the full cost out-of-pocket, meaning users generally cannot stack these prices with insurance coverage.
That detail matters because most Americans interact with drug pricing through insurers, pharmacy benefit managers, copays, deductibles, and negotiated rebates rather than by paying list price directly at the counter.
This structure also clarifies what TrumpRx is and is not. The site serves as a centralized hub for manufacturer-backed list-price discounts that bypass traditional insurance negotiation channels.
For those who want government to be smaller but effective, the appeal is obvious: the administration is using public visibility and deal-making to pressure prices down without creating a new entitlement.
At the same time, the narrow eligibility highlights how fragmented U.S. healthcare remains.
Why the Humira number matters in the broader pricing debate
Humira’s headline discount is politically potent because it demonstrates how far list prices can drift from what many insured patients actually pay after negotiations.
The reporting explicitly contrasts the uninsured experience—facing list prices above $6,900—with the reality that insured patients often pay less due to negotiated arrangements.
TrumpRx targets that gap: it does not replace insurance pricing so much as it offers a relief valve for people excluded from the negotiated system.
That dynamic helps explain why bipartisan anger keeps building, even when Washington claims progress.
When prices are “solved” inside opaque rebate structures, families who lack coverage—or who fall into high-deductible periods—can still face startling bills. TrumpRx’s approach effectively admits the problem: the list price is the pain point for the uninsured.
The tradeoff is scope: a growing menu of drugs still leaves many conditions, brands, and patients outside the program.
What happens next: more deals, but limited reach without system reform
The administration’s timeline, as described in the reporting, shows a steady expansion: a Genentech deal announced in December 2025, an AbbVie agreement reached in January 2026, and a February 2026 launch that has now grown to more than 61 drugs.
That trajectory could encourage additional companies to join, especially if the alternative is heavier regulation.
Still, the available details do not show how quickly TrumpRx can scale beyond a targeted, uninsured-focused niche.
For voters across the political spectrum who suspect the system serves entrenched interests, the TrumpRx rollout underscores two realities at once.
First, concentrated federal leverage can sometimes extract real, immediate savings for vulnerable patients.
Second, the fact that Americans need a White House website to access prices closer to affordability is itself an indictment of how disconnected list pricing, insurance middlemen, and patient costs have become.
The reporting provides limited outside expert commentary, so the long-term impact remains uncertain.
Sources:
Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx
Two more drug companies to officially launch on TrumpRx
